IMMUNE PHARMACEUTICALS INC. (NASDAQ:IMNP) Files An 8-K Other Events
Item 8.01
| Other Events. |
On March 13, 2017, Immune Pharmaceuticals Inc. (the
Company) issued a press release
announcing that The Nasdaq Stock Market LLC
(Nasdaq) granted its request for
continued listing, subject to the Company effecting a reverse
stock split on or before April 14, 2017, and evidencing
compliance with the $1.00 minimum bid price requirement set forth
in the Nasdaq Listing Rule 5550(a)(2) on or before May 1, 2017. A
copy of the press release is attached as an exhibit to this
report and is incorporated by reference herein.
| Item 9.01 | Financial Statements and Exhibits. |
| (d) | Exhibits |
| 99.1 |
Press release, dated March 13, 2017. |
About IMMUNE PHARMACEUTICALS INC. (NASDAQ:IMNP)
Immune Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of targeted therapeutics in the fields of immuno-inflammation and immuno-oncology. The Company’s segment is acquiring, developing and commercializing prescription drug products. Its Immuno-inflammation product pipeline includes bertilimumab, a fully human antibody targeting eotaxin-1, a regulator of immuno-inflammation; a portfolio of immune oncology products, and NanoCyclo, a topical nanocapsule formulation of cyclosporine-A, for the treatment of atopic dermatitis and psoriasis. Its immuno-oncology pipeline includes Ceplene, a small molecule targeting the Histamine-2 Receptor to overcome immunosuppression in Acute Myeloid Leukemia and other malignancies. Azixa and crolibulin are vascular disrupting agents. NanomAbs is a technology platform that allows the targeted delivery of chemotherapeutics into cancer cells. IMMUNE PHARMACEUTICALS INC. (NASDAQ:IMNP) Recent Trading Information
IMMUNE PHARMACEUTICALS INC. (NASDAQ:IMNP) closed its last trading session down -0.003 at 0.165 with 2,222,501 shares trading hands.